Solasia Pharma K.K. (4597.T)
Tokyo · JPY · Healthcare · Drug Manufacturers - Specialty & Generic
¥28 (+3.70%) as of
Key statistics
- Market cap
- 7.64B
- Forward P/E
- -13.33
- EPS (TTM)
- -3.29
- Dividend yield
- 0.00%
- 52-week range
- 21.00 – 42.00
- Beta
- 1.18
- Revenue (TTM)
- 388M
- Profit margin
- -231.96%
- Volume
- 96.79M
About Solasia Pharma K.K.
Solasia Pharma K.K. develops, markets, imports, and exports pharmaceutical products and medical devices in Japan, China, South Korea, and internationally. The company offers Episil (SP-03), an oral liquid for oral mucositis/stomatitis; DARVIAS (SP-02), an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma; and Sancuso (SP-01) for chemotherapy-induced nausea and vomiting. It also develops SP-04, which is in a preclinical trial for chemotherapy-induced peripheral neuropathy; and SP-05, which is in a preclinical trial for colorectal cancer. The company was formerly known as JapanBridge, Inc. and changed its name to Solasia Pharma K.K. in September 2008. Solasia Pharma K.K. was founded in 2006 and is headquartered in Minato, Japan.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Minato, Japan
- Employees
- 22
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.